Details of the antenatal characteristics of the 70 pregnancies (74 infants for 70 pregnancies because of 4 twin sets)
| n (%) | |
|---|---|
| Adverse events during pregnancy: | 26 (37%) |
| Spotting/bleeding | 8 (11) |
| Placental abruptio | 6 (9) |
| Premature contractions | 4 (6) |
| Chronic HIV infection | 3 (4) |
| HELLP syndrome | 2 (3) |
| Placental chorioangioma | 1 (2) |
| Cervical cerclage | 1 (2) |
| Presence of autoantibodies | 1 (2) |
| Maternal CMV Serology (first trimester) | |
| CMV negative | 39 (53%) |
| CMV immune | 30 (41%) |
| Proven seroconversion during pregnancy | 1 (1%) |
| Unknown maternal status | 4 (5%) |
| Drug/medication: | 21 (30%) |
| β-Blocker | 6 (9) |
| Tetrahydrocannabinol | 4 (6) |
| Cocaine | 3 (4) |
| Nicotine | 3 (4) |
| Combivir | 3 (4) |
| Benzodiazepine | 2 (3) |
| Antidepressants | 2 (3) |
| HIV Tritherapy | 2 (3) |
| Valproate | 1 (2) |
| Prednisone | 1 (2) |
| Euthyrox | 1 (2) |
| Assisted reproduction: | 13 (19%) |
| In vitro fertilization | 8 (11) |
| Hormonal stimulation | 4 (6) |
| Pathological Doppler (Class II or III associated with IUGR) | 6 (9%) |
| Total antenatal factors combined | 44 (63%) |
CMV, cytomegalovirus; IUGR, intrauterine growth restriction.